SEC Form 4 · accession 0000899243-18-012670
EyePoint, Inc. · EYPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James J Barry
Director
Period of report
May 7, 2018
Accepted (ET)
May 14, 2018 · 4:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001314102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 7, 2018 | M | 12,500 | — | A | 12,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitsF1,F2 | — | May 7, 2018 | M | 12,500 | D | — | — | Common Stock | 12,500 | 0 | D |
Explanation of responses
- F1Each deferred stock unit represents the right to receive one share of the common stock of EyePoint Pharmaceuticals, Inc.
- F2On December 15, 2017, the reporting person was granted 12,500 deferred stock units, which deferred stock units vested in full in connection with the effectiveness of Mr. Barry's resignation from the Board on May 7, 2018.